Drug Delivery Patents

Drug delivery patents span lipid nanoparticle (LNP) formulation; polymer microspheres; transdermal systems; oral absorption enhancement; and targeted delivery — with major activity from specialty formulation companies; pharmaceutical companies; contract development and manufacturing organizations (CDMOs); and ADC developers: MAJOR DRUG DELIVERY PATENT HOLDERS: LNP DRUG DELIVERY (BEYOND RNA): ARBUTUS BIOPHARMA (FORMERLY INEX/PROTIVA): 200+; specific ionizable lipid LNP for small molecule + specific nucleic acid co-delivery (specific specific lipid nanoparticle: specific specific ionizable lipid DLin-DMA/MC3/KC2 + specific specific helper lipid DSPC + specific specific cholesterol + specific specific PEG-lipid for specific specific pH-responsive endosomal escape); PRECISION NANOSYSTEMS (BD); ALNYLAM; MODERNA: specific specific lipid nanoparticle formulation optimization (specific specific microfluidic mixing process for specific specific particle size control 60-100 nm PDI + specific specific encapsulation efficiency >90% from specific specific flow ratio + specific specific flow rate parameter); POLYMER MICROSPHERE CONTROLLED RELEASE: EVONIK INDUSTRIES (PLGA SUPPLIERS): 1,000+; specific poly(lactic-co-glycolic acid) PLGA microsphere (specific specific PLGA MW + specific specific LA:GA ratio 50:50 / 75:25 for specific specific degradation rate control: specific specific half-life 1-6 weeks for specific specific sustained release of specific specific peptide/small molecule for specific specific once-monthly injection vs. specific specific daily oral); specific PLGA microsphere manufacturing (specific specific solvent evaporation: specific specific O/W emulsion or specific specific S/O/W for specific specific protein encapsulation with specific specific particle size 10-100μm + specific specific drug loading 10-30%); ALKERMES (VIVITROL; RISPERDAL CONSTA): 500+; specific injectable depot microsphere (specific specific PLGA naltrexone-loaded injectable depot + specific specific aqueous suspension for specific specific monthly injection substitution of specific specific daily oral); TRANSDERMAL DRUG DELIVERY: LTS LOHMANN; TESA LABTEC; 3M DRUG DELIVERY: 2,000+ transdermal patch patents; specific drug-in-adhesive (DIA) transdermal patch (specific specific EVA copolymer matrix with specific specific drug dissolved/suspended for specific specific controlled diffusion through specific specific rate-controlling membrane for specific specific specific flux target μg/cm2/hr); specific iontophoretic transdermal (specific specific Zosano Pharma, Noven: specific specific small direct current for specific specific drug ion migration at specific specific dose rate with specific specific electrode chamber configuration); ANTIBODY DRUG CONJUGATE (ADC): SEAGEN/PFIZER; IMMUNOMEDICS (GILEAD); ROCHE: 1,000+ ADC linker+payload patents; specific ADC site-specific conjugation (specific specific engineered cysteine or specific specific non-natural amino acid for specific specific specific drug-antibody ratio DAR control vs. specific specific stochastic lysine conjugation); specific ADC cleavable linker (specific specific pH-sensitive hydrazone or specific specific protease-cleavable Val-Cit-PABC for specific specific tumor-selective payload release).

Nanoparticle active targeting; oral bioavailability enhancement for poorly soluble drugs; and sustained-release depot formulations represent three of the most commercially important and IP-rich areas of drug delivery — each with distinct technical and regulatory patentability considerations: NANOPARTICLE TARGETING PATENTS: MIT; UNIVERSITY OF TORONTO; BIND BIOSCIENCES; SORRENTO; CALANDO: specific active-targeted nanoparticle (specific specific surface functionalization: specific specific folate receptor ligand + specific specific PSMA aptamer + specific specific HER2 antibody fragment covalently conjugated to specific specific nanoparticle surface via specific specific PEG spacer for specific specific tumor cell receptor-mediated endocytosis with specific specific measured uptake ratio tumor:non-tumor); specific passive EPR targeting (specific specific 100-200 nm PEGylated nanoparticle for specific specific enhanced permeability and retention EPR effect in specific specific tumor vasculature with specific specific measured tumor accumulation vs. specific specific free drug by specific specific biodistribution study); ORAL BIOAVAILABILITY ENHANCEMENT PATENTS: ASHLAND (KLUCEL; PLASDONE); EVONIK (EUDRAGIT); BEND BIOSCIENCE; LONZA; LUBRIZOL: specific amorphous solid dispersion ASD (specific specific hot melt extrusion HME: specific specific drug + specific specific HPMC-AS or specific specific PVP-VA polymer extruded at specific specific Tg+30°C for specific specific amorphous drug dispersion stabilized by specific specific polymer molecular interaction for specific specific specific X-fold bioavailability enhancement of specific specific BCS class II/IV drug vs. specific specific crystalline API); specific nanocrystal (specific specific wet media milling using specific specific Pearl Mill or specific specific Microfluidizer at specific specific specific energy for specific specific 100-500 nm drug nanocrystal with specific specific stabilizer HPMC+SDS for specific specific specific surface area enhancement + specific specific specific dissolution rate improvement); specific self-emulsifying drug delivery system SEDDS (specific specific lipid-based formulation: specific specific surfactant HLB 12-14 + specific specific co-solvent + specific specific oil for specific specific spontaneous emulsification in specific specific GI fluid with specific specific specific droplet size <200 nm for specific specific lymphatic absorption pathway for specific specific BCS class II drugs); SUSTAINED-RELEASE DEPOT PATENTS: SANDOZ; TOLMAR; ATRIGEL (TOLMAR); CAMURUS: specific in situ forming implant (specific specific Atrigel PLGA dissolved in specific specific NMP solvent + specific specific drug for specific specific subcutaneous injection → specific specific phase inversion + specific specific water diffusion for specific specific PLGA precipitation → specific specific drug depot with specific specific specific controlled release period 1-6 months); specific crystalline depot (specific specific Camurus FluidCrystal: specific specific lipid cubic phase or specific specific hexagonal liquid crystal for specific specific specific viscous injection depot sustained release of specific specific peptide/protein).

Antibody drug conjugates (ADCs); inhaled drug delivery; and delivery systems for cell and gene therapies represent three of the fastest-growing patent areas in drug delivery — driven by the commercial success of ADC cancer drugs; respiratory biologics; and the gene therapy revolution: ANTIBODY DRUG CONJUGATE (ADC) PATENT LANDSCAPE: SEAGEN/PFIZER; IMMUNOMEDICS/GILEAD; ROCHE/GENENTECH; DAIICHI SANKYO: specific ADC format innovations: specific ADC payload (specific specific monomethyl auristatin E MMAE + specific specific MMAF tubulin polymerization inhibitor for specific specific Seagen ADCs: specific specific brentuximab vedotin + specific specific enfortumab vedotin; specific specific deruxtecan DXd topoisomerase I inhibitor for specific specific DS-8201 T-DXd trastuzumab deruxtecan Enhertu; specific specific DM1/DM4 maytansine microtubule inhibitor for specific specific Roche ado-trastuzumab emtansine Kadcyla); specific ADC linker (specific specific Seagen maleimide-caproyl-Val-Cit-PABC protease-cleavable bystander-active linker for specific specific tumor intracellular lysosomal cathepsin cleavage + specific specific bystander killing; specific specific succinimide thioether non-cleavable for specific specific Kadcyla intracellular catabolism); INHALATION DRUG DELIVERY PATENTS: AstraZeneca; GSK; Novartis; Boehringer Ingelheim; Vectura (Haleon): specific dry powder inhaler DPI (specific specific Turbuhaler/Handihaler/Ellipta: specific specific carrier-drug blend aerosolization: specific specific lactose carrier + specific specific fine particle API for specific specific deagglomeration by specific specific inspiratory flow for specific specific MMAD 1-5μm respirable fraction for specific specific deep lung deposition); specific soft mist inhaler SMI (specific specific Respimat: specific specific two impinging liquid jets for specific specific soft mist generation without specific specific propellant for specific specific specific <5 μm droplet MMAD for specific specific improved lung deposition vs. specific specific pMDI); specific pressurized metered dose inhaler pMDI (specific specific HFA 134a/227 propellant + specific specific co-solvent + specific specific drug suspension for specific specific specific 50-100 μL metered spray); CELL AND GENE THERAPY DELIVERY PATENTS: SPARK THERAPEUTICS; REGENXBIO; BIOMARIN; GENZYME (SANOFI); BLUEBIRD BIO: specific AAV capsid engineering (specific specific rational design or specific specific directed evolution of specific specific AAV capsid protein for specific specific tissue tropism: specific specific AAVrh10 liver + CNS; specific specific AAV9 CNS; specific specific modified capsid surface loop for specific specific immune evasion at specific specific specific neutralizing antibody seropositivity); specific LNP for mRNA gene therapy delivery (specific specific ionizable LNP composition for specific specific hepatic or specific specific extra-hepatic tissue delivery: specific specific SORT selective organ targeting via specific specific lipid component addition; specific specific MC3+DSPC+cholesterol+PEG2000-DMG standard hepatic formulation).

Drug delivery startups — operating at the intersection of chemistry; materials science; pharmacology; and regulatory science — have strong opportunities to build defensible IP around novel formulation compositions; manufacturing processes; and specific delivery system designs: DRUG DELIVERY STARTUP IP STRATEGY: UNDERSTAND THE DRUG DELIVERY IP LANDSCAPE: COMPOSITION OF MATTER IS STRONGEST: specific novel formulation composition with specific measured pharmacokinetic improvement (AUC; Cmax; T1/2; bioavailability; drug loading; release rate) = highly patent-eligible composition of matter or method of treatment claims; no § 101 risk for formulation IP — chemistry is not abstract; § 103 IS THE PRIMARY CHALLENGE: formulation combinations face obviousness challenges if each component is individually known; SURVIVAL: specific measured unexpected result (specific specific X-fold bioavailability improvement beyond what skilled formulator would predict from component properties); specific specific synergistic combination effect beyond additive); REGULATORY STRATEGY OVERLAPS IP: 505(b)(2) NDA for new formulation of approved drug = regulatory pathway that leverages formulation IP without full clinical program; Orange Book listing for formulation patents on approved products creates 30-month stay regulatory protection under Hatch-Waxman; WHEN TO PATENT IN DRUG DELIVERY: SPECIFIC NOVEL LNP COMPOSITION: specific novel ionizable lipid structure + specific specific lipid composition ratio + specific specific particle size + specific measured encapsulation efficiency + specific specific measured in vivo delivery to specific specific organ (measured by bioluminescence imaging or specific specific tissue harvest biodistribution at specific specific dose); SPECIFIC NOVEL POLYMER MICROSPHERE: specific novel PLGA MW + LA:GA ratio + specific manufacturing process parameters + specific measured drug release profile (specific specific in vitro release rate over specific specific time period matching specific specific in vivo PK); SPECIFIC NOVEL ORAL FORMULATION: specific novel ASD polymer + drug combination with specific measured specific specific X-fold bioavailability improvement vs. crystalline API on specific specific animal model or specific specific human crossover PK study (unexpected result anchors non-obviousness); SPECIFIC NOVEL TRANSDERMAL FORMULATION: specific novel adhesive matrix composition + specific measured flux rate μg/cm2/hr through specific specific cadaver skin in specific specific Franz cell permeation study; SPECIFIC NOVEL ADC FORMAT: specific novel site-specific conjugation chemistry + specific specific linker-payload combination with specific measured DAR distribution + specific specific bystander effect + specific specific in vitro cytotoxicity vs. comparator ADC; TRADE SECRETS: specific drug-polymer interaction parameters for specific specific formulation (specific specific specific molecular dynamics simulation calibrated to specific specific specific measured dissolution); specific specific manufacturing scale-up process parameters (specific specific specific spray-drying inlet temperature + specific specific specific feed rate + specific specific specific outlet temperature for specific specific specific ASD particle morphology); specific specific HME screw design + temperature profile; KEY FTO: Arbutus/Moderna/Acuitas LNP ionizable lipid IP; Evonik PLGA microsphere polymer formulation; Alkermes PLGA injectable depot; 3M/LTS transdermal DIA patch; Seagen Val-Cit-PABC protease linker; Daiichi Sankyo deruxtecan DXd payload; AstraZeneca/GSK inhaler device mechanism; Spark/Regenxbio AAV capsid engineering.